Chinese inflammatory disease biotech Connect Biopharma sets terms for $150 million US IPO

Connect Biopharma Holdings, a Chinese Phase 2 biotech developing therapies for T cell-driven inflammatory diseases, announced terms for its IPO on Friday.

The Taicang, China-based company plans to raise $150 million by offering 9.4 million ADSs at a price range of $15 to $17. AtRead More